Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by StockNews.com
StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating in a research note released on Friday morning. Several other research analysts also recently issued reports on NBIX. Piper Sandler upped their price target on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock […]
More Stories
Monthly Payments for Homes Increased 1st Time in 6 Months
By Naveen Athrappully The median monthly mortgage payment in the United States hit $2,742 for the four weeks ending March...
Trump’s 3D Chess: How President Trump Is Checkmating China and Russia by Toppling Their Oil Proxies in Venezuela, Cuba, and Iran
By Stephen Zogopoulos, USNN World News In the rarefied world of grand strategy, true masters don’t play on a flat...
Iran Vows Lasting Grip on Strait of Hormuz After War
By Tom Ozimek Iran has signaled that it intends to exert lasting control over the Strait of Hormuz—the world’s most...
Trump Signs Memo to Pay All DHS Employees During Shutdown
By Troy Myers President Donald Trump on Friday signed a memorandum directing the Department of Homeland Security (DHS) to pay...
Best Photo Editing Apps in 2026: Features, Pricing, and Limitations
Finding the best photo editing app in 2026 has become difficult. With several Android and iOS editing tools available in...
In the Mud Season 3: Release Date, Cast, Trailer, and Spoiler
If you have already watched the first two seasons of In the Mud, then you must also be curious about...